AstraZeneca and Bristol Myers Squibb became the subject of merger rumors earlier this month, with the Financial Times reporting the two blue chip pharmaceutical companies were close to a deal that would create an oncology-focused powerhouse worth around $400 billion. Investors reacted negatively to the rumors, pushing AstraZeneca shares down by around 9% after they first emerged, and subsequent headlines suggest the proposed merger is unlikely to happen. Analysts note that while the combined entity would have substantial synergies in oncology, its massive market share would face significant antitrust scrutiny, and AstraZeneca would also inherit Bristol Myers Squibb's looming patent cliffs for drugs like Eliquis and Opdivo. The article suggests AstraZeneca shareholders may benefit more from the company continuing to grow organically rather than pursuing a megadeal, while Bristol Myers Squibb trades at less than 10 times forward earnings with its own headwinds already priced in.
